Vincent ARANZANA-CLIMENT

Associate Professor

University of Poitiers

France

Research Interests

Explore related searches

Professors in France

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Vincent Aranzana-Climent is an Associate Professor at Université de Poitiers, France. His research focuses on pharmacokinetics and pharmacodynamics, with recent articles exploring models for antimicrobial resistance, drug development, and the pharmacokinetic behavior of various antibacterial agents. His work aims to enhance the understanding of drug distribution and effectiveness in treating infections.

Articles (14)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Collaborators (9)

Jon Ulf Hansen

Statens Serum Institut

DENMARK

View details

Alexia Chauzy

Assistant Professor

University of Poitiers

FRANCE

View details

Małgorzata Urbaś

POLAND

View details

Noémie Prébonnaud

University of Poitiers

FRANCE

View details

Brenda de Winter

Hospital Pharmacist - Assistant Professor

Erasmus University Medical Center

NETHERLANDS

View details

Lena Friberg

Professor

Uppsala University

SWEDEN

View details

Anouk Muller

department of pathology erasmus university medical center rotterdam the netherlands

NETHERLANDS

View details

Sanne van den Berg

assistant professor

Erasmus MC

NETHERLANDS

View details

Elisabet I. Nielsen

SWEDEN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Vincent ARANZANA-CLIMENT

Research Interests

Explore related searches

Contact this professor

About

Articles (14)

Model-informed drug development for antimicrobials: translational pharmacokinetic-pharmacodynamic modelling of apramycin to facilitate prediction of efficacious dose in complicated urinary tract infections

A freely accessible, adaptable hollow-fiber setup to reproduce first-order absorption: illustration with linezolid cerebrospinal fluid pharmacokinetic data

Prediction of higher ceftazidime–avibactam concentrations in the human renal interstitium compared with unbound plasma using a minimal physiologically based pharmacokinetic model developed in rats and pigs through microdialysis

An integrative and translational PKPD modelling approach to explore the combined effect of polymyxin B and minocycline against Klebsiella pneumoniae.

Integration of individual preclinical and clinical anti-infective PKPD data to predict clinical study outcomes.

Pharmacokinetic and pharmacodynamic properties of polymyxin B in Escherichia coli and Klebsiella pneumoniae murine infection models

Characterization of <i>Pseudomonas aeruginosa</i> resistance to ceftolozane-tazobactam due to <i>ampC</i> and/or <i>ampD</i> mutations observed during treatment using semi-mechanistic PKPD modeling.

Expert workshop summary: Advancing toward a standardized murine model to evaluate treatments for antimicrobial resistance lung infections.

Variability of murine bacterial pneumonia models used to evaluate antimicrobial agents.

Translational in vitro and in vivo PKPD modelling for apramycin against Gram-negative lung pathogens to facilitate prediction of human efficacious dose in pneumonia.

A Minimal Physiologically Based Pharmacokinetic Model to Characterize CNS Distribution of Metronidazole in Neuro Care ICU Patients

Pharmacokinetic/pharmacodynamic models for time courses of antibiotic effects

PKPD Modeling of the Inoculum Effect of <i>Acinetobacter baumannii</i> on Polymyxin B <i>in vivo</i>.

A new PKPD model to characterize the inoculum effect of <i>Acinetobacter baumannii</i> on polymyxin B <i>in vitro</i>.

Collaborators (9)

Jon Ulf Hansen

Alexia Chauzy

Małgorzata Urbaś

Noémie Prébonnaud

Brenda de Winter

Lena Friberg

Anouk Muller

Sanne van den Berg

Elisabet I. Nielsen

Make your next move.